Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, EOM Pharmaceutical Holdings's Enterprise Value is $16.46 Mil.
EOM Pharmaceutical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2018 was $-10.93 Mil. Therefore, EOM Pharmaceutical Holdings's EV-to-FCF for today is -1.51.
The historical rank and industry rank for EOM Pharmaceutical Holdings's EV-to-FCF or its related term are showing as below:
IMUC'
s EV-to-FCF Range Over the Past 10 Years
Min: -2.75 Med: 0 Max: 0
Current: -1.51
IMUC's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 14.835
vs IMUC: -1.51
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EOM Pharmaceutical Holdings's PE Ratio (TTM) for today is calculated as:
EOM Pharmaceutical Holdings's share price for today is $0.1301.
EOM Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.732.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
EOM Pharmaceutical Holdings EV-to-FCF Related Terms
EOM Pharmaceutical Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, EOM Pharmaceutical Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EOM Pharmaceutical Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where EOM Pharmaceutical Holdings's EV-to-FCF falls into.
EOM Pharmaceutical Holdings's current Enterprise Value is $16.46 Mil.
EOM Pharmaceutical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EOM Pharmaceutical Holdings (IMUC) has a EV-to-FCF of -1.51 as of Jul. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' EV-to-FCF too high?
EOM Pharmaceutical Holdings' current EV-to-FCF is -1.51.
How does EOM Pharmaceutical Holdings' EV-to-FCF compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' EV-to-FCF of -1.51 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 14.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.84, based on 344 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on EOM Pharmaceutical Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EOM Pharmaceutical Holdings's current EV-to-FCF is -1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current EV-to-FCF of -1.51. The current EV-to-FCF is -1.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current EV-to-FCF is -1.51 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMUC has been successfully added to your 
